2nd edition .
This Framework applies to the sharing of H5N1 and other influenza viruses with human pandemic potential and the sharing of benefits. This Framework does not apply to seasonal influenza viruses or other non-influenza pathogens or biological substances that may be contained in clinical ...specimens shared under this Framework
This second edition of the Pandemic Influenza Preparedness (PIP) Framework reflects an amendment to Annex 2, Standard Material Transfer Agreement 2, Footnote 1, that was adopted by the Seventy-second World Health Assembly in May 2019.The amendment clarifies that, under certain circumstances, the indirect use of PIP Biological Materials will require the conclusion of an SMTA2. The amendment is in effect from the closure of the Seventy-second World Health Assembly (28 May 2019).
more
The regional Migrant Response Plan (MRP) for the Horn of Africa and Yemen includes urgent life-saving humanitarian and protection interventions to improve safe and dignified access to basic services for migrants and host communities while ensuring medium- to long-term actions aimed at addressing the... drivers of migration.
more
Esta orientação provisória foi desenvolvida com base na recomendação emitida pelo Grupo Consultivo Estratégico de Especialistas (SAGE) em imunização, em sua reunião extraordinária de 5 de janeiro de 2021, e atualizada durante sua reunião extraordinária de 27 de maio de 2021 (2), sendo no...vamente atualizada em 19 de novembro de 2021 e em 19 de janeiro de 2022. Foram coletadas as declarações de interesses de todos os colaboradores externos, sendo elas avaliadas quanto a quaisquer conflitos de interesse. Os resumos dos interesses relatados podem ser encontrados no site da reunião do SAGE e no site do Grupo de Trabalho do SAGE. A orientação se baseia em evidências resumidas no documento de referência sobre a vacina de mRNA BNT162b2 (Pfizer-BioNTech) contra COVID-19 (4), sendo novamente atualizado com base em novos dados provenientes de publicações científicas.
more
Lancet Public health 2022 January 6, 2022 https://doi.org/10.1016/ S2468-2667(21)00249-8
Growth in the number of individuals living with dementia underscores the need for public health planning efforts and policy to address the needs of this group. Country-level estimates can be used to inform nati...onal planning efforts and decisions. Multifaceted approaches, including scaling up interventions to address modifiable risk factors and investing in research on biological mechanisms, will be key in addressing the expected increases in the number of individuals affected by dementia.
more
The COVID-19 pandemic has led to large increases in healthcare waste, straining under resourced healthcare facilities and exacerbating environmental impacts from solid waste. This report quantifies the additional COVID-19 healthcare waste generated, describes current healthcare waste management syst...ems and their deficiencies, and summarizes emerging best practices and solutions to reduce the impact of waste on human and environmental health. The recommendations included in the report build on actions in the WHO manifesto for a healthy recovery from COVID-19: prescriptions and actionables for a healthy and green recovery. They target the global, national and facility levels to promote a “win–win” scenario for COVID-19 PPE use, testing and vaccinations that are safe and support environmental sustainability.
more
Lancet Infect Dis 2022;
22: 222–4
PHARMA’S RESPONSE TO THE COVID-19 VACCINES CRISIS. Update Feb., 14, 2022. In September 2021, Amnesty International published A Double Dose of Inequality, which assessed the extent to which the pharmaceutical industry was restricting access to Covid-19 vaccines. This report updates that assessment ...of five leading vaccine manufacturers, AstraZeneca plc, BioNTech SE, Johnson & Johnson, Moderna Inc., and Pfizer Inc. It also includes for the first time an assessment of the two largest Chinese vaccine producers, China National Pharmaceutical Group Co., Ltd. (Sinopharm) and Sinovac Biotech Ltd. (Sinovac).
more
22 Sept. 2021
The rapid development of effective Covid-19 vaccines in 2020 gave hope to the world in the darkest days of the deadly pandemic. However, the vaccine roll-out has been massively skewed towards wealthy nations. While rich states have hoarded vaccines, companies have also played a decisi...ve role in restricting fair access to a life-saving health product. This report focuses on six leading vaccine developers, AstraZeneca, BioNTech, Johnson & Johnson, Moderna, Novavax and Pfizer, assessing each company’s human rights policy, pricing structure, records on intellectual property, knowledge and technology sharing, allocation of available vaccine doses and transparency.
Available in Arabic, English, French, German and Spanish
more
This policy brief aims to provide a review of the current progress on implementing the Burkina Faso national action plan on AMR, identifies critical gaps, and highlights findings to accelerate further progress in the human health sector. The target audience includes all those concerned with implemen...ting actions to combat antimicrobial resistance in Burkina Faso.
more
O SAGE aplica os princípios da medicina baseada em evidências e estabeleceu um processo metodológico completo para emitir ou atualizar recomendações. Especificamente para vacinas contra a COVID-19, uma descrição detalhada dos processos metodológicos pode ser encontrada no esquema de evidênc...ias do SAGE para vacinas contra a COVID-19. Esse esquema contém orientações sobre como levar em consideração os dados provenientes de ensaios clínicos em apoio à emissão de recomendações baseadas em evidências específicas para vacinas.
more
scientific brief, 2 March 2022
A One Health Response. A Briefing Note